PLIANT THERAPEUTICS INC
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
PLRX$0.80-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Revenue | $— | $1,580 | $9,685 |
| Operating expenses: | |||
| Research and development | (169,310) | (127,797) | (96,936) |
| General and administrative | (59,055) | (57,928) | (39,949) |
| Total operating expenses | (228,365) | (185,725) | (136,885) |
| Loss from operations | (228,365) | (184,145) | (127,200) |
| Interest and other income (expense), net | 21,085 | 24,076 | 4,670 |
| Interest expense | (3,024) | (1,267) | (791) |
| Net loss | $(210,304) | $(161,336) | $(123,321) |
| Net loss per share - basic and diluted | $(3.47) | $(2.75) | $(2.94) |
| Weighted average shares used in computing net loss per share - basic and diluted | 60,538,639 | 58,719,083 | 42,015,908 |
| Comprehensive loss: | |||
| Net loss | $(210,304) | $(161,336) | $(123,321) |
| Net unrealized (loss) gain on short-term investments | (24) | 2,303 | (1,757) |
| Total other comprehensive (loss) gain | (24) | 2,303 | (1,757) |
| Comprehensive loss | $(210,328) | $(159,033) | $(125,078) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.